St. Jude Care & Treatment

Menu

Close

Recruiting

PEPN2111: Phase 1/2 Trial of CBL0137 for Relapsed or Refractory Solid Tumors and Lymphoma

About this study

This is a clinical trial of a cancer-fighting medicine called CBL0137. Doctors want to learn how this medicine works in young patients with cancer that has come back after treatment (relapsed) or did not get better after treatment (refractory).

CBL0137 is experimental. This means it has not been proven to work in children with these types of cancer. Researchers want to learn more about CBL0137 because it seems to work against cancer in test tubes and animals. CBL1037 has been used in adults with cancer, but there is a lot we do not know about it yet.

In this study, you will be given CBL0137 through a vein. There are 17 cycles of therapy. Each cycle lasts 21 days. The entire study treatment will last about 12 months.

Eligibility overview

  • 12 months to 21 years old with diagnosis of:
    • Relapsed or refractory solid tumor or lymphoma (including CNS tumors) OR
    • Progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy
  • 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma

Request a referralLearn about clinical research

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

A Phase 1/2 Trial of CBL0137 in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma

Study goal:

The main purpose of this study is to find the highest, safest dose of CBL0137 that can be given to children, teens and young adults with solid tumors or lymphoma.

Diagnosis:

Solid Tumor, Lymphoma, Brain Tumor, DMG

Age:

12 months to 21 years old with diagnosis of relapsed or refractory solid tumor or lymphoma (including CNS tumors) or progressive or recurrent DIPG or other H3 K27M-mutant diffuse midline gliomas previously treated with radiation therapy; 12 months to 30 years old with diagnosis of relapsed or refractory osteosarcoma

Clinical trials categories:

Solid Tumors

Diffuse Midline Glioma

Childhood Cancer Osteosarcoma Diffuse Intrinsic Pontine Glioma (DIPG) Lymphoma

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more